Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy

AIMS: Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced oxidative stress and energy depletion. Unbound/loosely bound tissue copper II ions are powerful catalysts of oxidative stress and inhibitors of antioxidants. Trientine is a h...

Descripción completa

Detalles Bibliográficos
Autores principales: Farrant, John, Dodd, Susanna, Vaughan, Carly, Reid, Anna, Schmitt, Matthias, Garratt, Clifford, Akhtar, Mohammed, Mahmod, Masliza, Neubauer, Stefan, Cooper, Robert M, Prasad, Sanjay K, Singh, Anvesha, Valkovič, Ladislav, Raman, Betty, Ashkir, Zakariye, Clayton, Dannii, Baroja, Olatz, Duran, Beatriz, Spowart, Catherine, Bedson, Emma, Naish, Josephine H, Harrington, Chris, Miller, Christopher A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Study Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359575/
https://www.ncbi.nlm.nih.gov/pubmed/37137675
http://dx.doi.org/10.1136/heartjnl-2022-322271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359575/
https://www.ncbi.nlm.nih.gov/pubmed/37137675
http://dx.doi.org/10.1136/heartjnl-2022-322271

Ejemplares similares